NEW YORK – September 17, 2018 – Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo Clinic studies showing that direct blood volume analysis provides doctors with important information to inform treatment, and does so at an advantage over surrogate measurements, including cardiac filling pressure and kidney function. The studies were presented Saturday, September 15, 2018 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Nashville, Tenn.
“In each study, we compared blood volume analysis to a surrogate marker to understand the best way to treat heart failure and, in one study, heart failure with accompanying kidney disease. Both studies demonstrated that accurate blood volume measurement provided important information for physicians to better treat individual cases of fluid overload and potentially reduce additional complications,” said Wayne L. Miller, M.D., Ph.D., Mayo Clinic, who was the lead author of both studies. “Both of these posters underscore the value of accurate blood volume measurement as a means of reducing mortality in this complex to treat patient population.”
One poster, “Volume and Pressure in Heart Failure – Complimentary, But Not Two Sides of the Same Coin,” showed the distinction between blood volume analysis and cardiac volume pressure (CVP), which is a surrogate marker for fluid volume expansion and overload in heart failure patients. The study concludes that while both demonstrate value, there is no substitute for clear measurement of fluid volume, as CVP does not accurately reflect volume status, and therefore should be an additional measure to blood volume analysis rather than a substitute when making treatment decisions in heart failure patients with potential volume overload. The second poster, “Volume-Kidney Interaction in Chronic Heart Failure – Impact of Subclinical Volume Expansion and Chronic Kidney Disease on Clinical Outcomes,” showed that blood volume has a direct connection with kidney function, demonstrating additional risk in patients with both heart failure and impaired kidneys. Use of the BVA-100 provided investigators with accurate plasma volume measurement in order to assess total risk.
“We continue to receive support from the medical community that reflects our long-held conclusion that direct blood volume measurement in the heart failure setting is vital to establishing personalized and optimized treatment,” said Michael Feldschuh, CEO of Daxor Corporation. “These two posters, which were independently presented from one of the leading medical institutions at the preeminent heart failure conference in the United States, clearly demonstrate the BVA-100 as the most accurate means to establish blood volume in these circumstances, and to help physicians best determine treatment options to optimize outcomes.”
About Daxor Corporation
Daxor Corporation is an innovative medical instrumentation and biotechnology company. The company manufactures the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. Daxor believes that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is the company’s goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately, its mission is to help hospitals and physicians incorporate Daxor’s BVA-100 diagnostic to significantly improve the quality of patient care. For more information please visit Daxor’s website at https://www.daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Sr. Managing Partner